Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

U.S. Sues Teva To Block Generic Drug

by Marc S. Reisch
March 28, 2011 | A version of this story appeared in Volume 89, Issue 13

The U.S. government has sued Teva Pharmaceutical Industries to block the sale of darunavir, a generic version of Johnson & Johnson’s Prezista protease inhibitor, used to treat HIV patients. In a filing in U.S. District Court for the District of New Jersey, the Justice Department asked FDA to withhold approval of darunavir until 2019, when a patent issued jointly to the National Institutes of Health and the University of Illinois expires. J&J’s Tibotec unit, which licenses the government patent and markets the drug, has filed a separate suit against Teva.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.